EUVIMEDObjevte EUVIMED
ÜbersichtsarbeitOpen access · CC BY-NC-ND 4.0

Seventeen years since rimonabant's downfall: reassessing its suicidality risk profile

Yuval Cohen, Andrew Kolodziej, Marshall Morningstar iD

Obesity · 2024

DOI: 10.1002/oby.24019 ↗

At a glance

Übersichtsarbeit in Obesity, 2024. Written by Yuval Cohen and 2 co-authors. Institution: Corbus Pharmaceuticals Holdings Inc., Norwood, Massachusetts, USA. Major MEDLINE topics: Rimonabant, United States Food and Drug Administration, Anti-Obesity Agents, Suicide. Cited 31 times so far (Crossref); 51 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Targeting the cannabinoid type 1 receptor (CB1) is a clinically validated antiobesity therapeutic approach. The only such drug approved, rimonabant, was launched in 2006 in Europe but subsequently rejected by the US Food and Drug Administration (FDA) in 2007. The FDA cited the increased risk of suicidality in its opposition to rimonabant's approval, leading to the drug's eventual worldwide withdrawal and the abandonment of this class of therapeutics. Seventeen years later, a new class of CB1‐targeting drugs is emerging, but the impact of the 2007 FDA decision remains a formidable obstacle to its clinical development. We revisit the suicidality data presented by the FDA in light of the evolution of suicidality assessment and cross‐reference this with the data in the subsequently published clinical trials. We conclude that the publicly available data do not support the FDA's conclusion that the use of rimonabant was associated with an increase in the risk of suicidality.

Subjects

MeSH terms (MEDLINE)

RimonabantUnited States Food and Drug AdministrationAnti-Obesity AgentsSuicideHumansUnited StatesObesityReceptor, Cannabinoid, CB1Cannabinoid Receptor AntagonistsDrug ApprovalPyrazolesPiperidines

Substances

RimonabantAnti-Obesity AgentsReceptor, Cannabinoid, CB1Cannabinoid Receptor AntagonistsPyrazolesPiperidines

Authors and institutions

  • Corbus Pharmaceuticals Holdings Inc., Norwood, Massachusetts, USA.

ORCID profiles: Marshall Morningstar

Cite

APA

Cohen, Y., Kolodziej, A., & Morningstar, M. (2024). Seventeen years since rimonabant's downfall: reassessing its suicidality risk profile. Obesity. https://doi.org/10.1002/oby.24019

Vancouver

Cohen Y, Kolodziej A, Morningstar M. Seventeen years since rimonabant's downfall: reassessing its suicidality risk profile. Obesity. 2024. doi:10.1002/oby.24019

BibTeX
@article{Cohen2024,
  author = {Cohen, Yuval and Kolodziej, Andrew and Morningstar, Marshall},
  title = {Seventeen years since rimonabant's downfall: reassessing its suicidality risk profile},
  journal = {Obesity},
  year = {2024},
  doi = {10.1002/oby.24019}
}
Start for free →